Aptus Pharma IPO GMP: Day 1 IPO Live Updates

Posted by : sachet | Tue Sep 23 2025

Check Expert’s Verdicts on Aptus Pharma IPO

The Aptus Pharma IPO GMP is ₹7 as of 23rd September 2025. It is a bookbuilding IPO of ₹13.02 crores, comprising a fresh issue of 0.19 crores. The issue will be listed on BSE and SME on its tentative listing date, 30th September 2025. The face value of Aptus Pharma shares stands at ₹10 per share, and the IPO price band is set at ₹65 to ₹70 per share. Retail investors can bid for a minimum of 2 lots of 4,000 shares worth ₹2,80,000.

Table of Contents

Aptus Pharma IPO Grey Market Premium

As of 23rd September 2025, the Aptus Pharma IPO GMP stands at ₹7 per share. Thus, the estimated listing price would be ₹77. This indicates that the estimated listing gain in this IPO could be 10.00%. However, GMP details are subject to change based on market conditions and fluctuations. Explore the table for the Aptus Pharma IPO GMP updates.

GMP Date	IPO Price	GMP	Estimated Listing Price	Estimated Listing Gains
23-09-2025	₹72.00	₹7.00	₹77.00	10.00%
22-09-2025	₹72.00	₹7.00	₹77.00	10.00%
21-09-2025	₹72.00	₹7.00	₹77.00	10.00%
20-09-2025	₹72.00	₹7.00	₹77.00	10.00%
19-09-2025	₹72.00	₹7.00	₹77.00	10.00%
18-09-2025	₹72.00	₹0.00	₹72.00	0.00%

Aptus Pharma IPO Details

IPO Open Date	23rd September 2025
IPO Close Date	25th September 2025
IPO Allotment Date	26th September 2025
Refund Initiation	29th September 2025
Issue Size	18,60,000 shares(aggregating up to ₹13.02 Cr)
Face Value	₹10 per share
Lot Size	2,000 shares
Issue Price Band	₹65.00 to ₹70.00 per share
Issue Type	Bookbuilding IPO
Listing At	BSE & SME
Listing Date	30th September 2025

Explanation

Aptus Pharma IPO: Aptus Pharma Limited has declared that the issue price is set at ₹65 to ₹70 per share. With this IPO, the company allows retail investors to bid for two lots of 4,000 shares worth ₹2,80,000. The face value of Aptus Pharma Limited shares is ₹10 per share. The shares of Aptus Pharma Limited will be listed on BSE and SME on its tentative listing day, 30th September 2025. Scroll down to view GMP updates and reviews of the Aptus Pharma IPO.

Objectives of the Aptus Pharma IPO

The primary aim of the Aptus Pharma IPO is to raise ₹13.02 crores. On the other hand, Aptus Pharma has decided to utilise these funds in different ways. Explore some of the secondary objectives for the Aptus Pharma IPO.

To Capital Expenditure for Office Premises with furniture and Industrial Racks
To Working Capital
For general corporate purposes

Aptus Pharma IPO Registrar

Bigshare Services Private Limited is the registrar of the Aptus Pharma IPO, responsible for managing the allotment procedure and initiating refunds. For any queries regarding the Aptus Pharma allotment and refund, please contact Bigshare Services Private Limited at investor@bigshareonline.com or +91-22-6263 8200.

Aptus Pharma IPO Review

The Aptus Pharma IPO has gained neutral ratings from industry experts, brokers, and institutional investors. Aptus Pharma Limited’s revenue increased by 38% from ₹17.88 crores in March 2024 to ₹24.64 crores in March 2025. Moreover, the company’s PAT rose by 288% from ₹0.80 crores to ₹3.10 crores. Most analysts recommend applying for this IPO to diversify your investment portfolio in the stock market. However, we’re waiting for further ratings to gain a better understanding and will continue to post them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Aptus Pharma IPO or not.

Aptus Pharma Limited Technicals

Key Indicators	Value
PE Ratio (Price-to-Earnings)	11.29
EPS (Earnings Per Share)	6.20
ROCE	45.66%
ROE	44.50%
RoNW	44.50%
PAT Margin	–
EBITDA Margin	19.31%
Price to Book Value	–
Market Capitalisation	₹48.02 Cr

The P/E ratio of Aptus Pharma Limited’s shares is 11.29, and its Earnings Per Share (EPS) stands at ₹ 6.20. Thus, the Aptus Pharma Limited IPO is expected to deliver gains on its tentative listing date, 30th September 2025.

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Aptus Pharma Limited are subject to change after the IPO. Refer to the table below for post-issue updates on these two metrics.

Indicators	Pre-IPO	Post-IPO
PE Ratio	11.29	4.52
EPS	6.20	4.52

FAQs on Aptus Pharma IPO

What is the GMP of the Aptus Pharma IPO?

Ans. As of 23rd September 2025, the Aptus Pharma (Grey Market Premium) stands at ₹7. This indicates that the estimated listing price could be ₹77 per share.

What is the issue price of the Aptus Pharma IPO?

Ans. The Aptus Pharma IPO price is set at ₹65.00 to ₹70.00 per share. Retail investors can apply for a minimum of 2 lots consisting of 4,000 shares worth ₹2,80,000. Moreover, HNIs are required to bid for a minimum of 3 lots (6,000 shares) worth ₹4,20,000.

Who is the registrar of the Aptus Pharma IPO?

Ans. Bigshare Services Private Limited is the registrar of the Aptus Pharma IPO, responsible for managing the allotment procedure and initiating refunds. For any queries regarding the Aptus Pharma allotment and refund, please contact Bigshare Services Private Limited at investor@bigshareonline.com or +91-22-6263 8200.

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Aptus Pharma IPO, download the Aptus Pharma IPO RHP and Aptus Pharma IPO DRHP. Conduct thorough research before investing in IPOs to minimise the risk of significant losses. You can also consult your financial advisor.